Asunción, Paraguay – May 29, 2025, Papasa, a long-standing pharmaceutical company in Paraguay, officially announced its transformation to a new name, Adium, celebrating its 50th anniversary. This name change is a strategic decision to integrate its identity as part of the Adium Group, which spans 18 countries across Latin America, and to solidify its corporate vision of improving human lives through innovative treatments.

 
50 Years of History and a New Beginning: A Global Leap from a Paraguayan Base

Established in Paraguay in 1975 as the group's first production facility, Papasa has played a crucial role in the Latin American pharmaceutical industry for the past 50 years. Led by Henry Lobo, Adium Paraguay plans to establish a consistent brand identity across the entire group through this rebranding and grow into a more trusted company for the community and patients.

This name change goes beyond a mere image refresh; it reaffirms the Adium Group's core objective, which has continued since 1975: to provide innovative treatments that positively change people's lives. Adium intends to strengthen its presence in Paraguay and continue its efforts to improve the quality of life for patients across various therapeutic areas.

 
Latin American Production Network and Innovation Partnerships

The Adium Group supplies high-quality medicines throughout Latin America through its five state-of-the-art production facilities located in Argentina, Brazil, Mexico, Paraguay, and Uruguay. These facilities meet the highest standards of quality and efficiency, contributing to increased access to medicines in the region.

Adium has particularly solidified its position as the "partner of choice" for global innovative companies. Through strategic alliances with over 10 multinational pharmaceutical companies based in North America, Europe, and Japan, including Amgen, Astellas, Bristol Myers Squibb (BMS), and Debiopharm, Adium is introducing cutting-edge therapies to the Latin American market. This allows them to provide innovative solutions to specialists in complex therapeutic areas such as oncology, hematology, cardiology, central nervous system disorders, urology, and gynecology, bringing positive changes to patients' lives.

 
Paraguay: Reaffirming its Status as a Production and Export Hub

Paraguay has reaffirmed its significant role as a production and export hub in the Adium Group's evolution. It produces over 45 million units of medicine annually and has expanded into 11 international markets, accounting for more than 50% of Paraguay's total pharmaceutical exports. Furthermore, it significantly contributes to the national economy by creating over 800 direct jobs.

Adium Paraguay currently boasts a product portfolio of over 180 items covering various specialties, including cardiology, psychiatry, gastroenterology, gynecology, traumatology, and diabetes. Through this, it provides a wide range of treatment options to Paraguayan patients and leads the way in health promotion.

 
A Leader in the Latin American Pharmaceutical Market

According to IQVIA, Adium has established itself as the 5th largest pharmaceutical company in the Latin American prescription drug market. The group employs over 7,300 people and is strengthening its position in high-complexity therapeutic areas through strong collaborations with international companies.

Moving forward, Adium will remain committed to improving the quality of life by supplying innovative treatments across Latin America, building on 50 years of expertise and trust, just as their slogan suggests: "Known as Papasa, but will be remembered as Adium." This name change marks a significant milestone as Adium begins its journey toward a new 50 years as a leader in the Latin American pharmaceutical industry.